adventure – Next Phase Newsletter

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is excited to welcome Bayer Co.Lab as a Title Sponsor of RESI Boston 2026, taking place September 22-23 at the Westin Copley Place in Boston, with virtual partnering continuing September 25 and 28-29.

Bayer Co.Lab is Bayer’s global network of life science incubators supporting early-stage entrepreneurs developing breakthrough technologies. By connecting emerging companies with scientific expertise, mentorship, infrastructure, and Bayer’s broader global network, Co.Lab provides an environment designed to help innovators advance promising science and build the relationships needed for future growth.

Bayer Co.Lab’s mission is closely aligned with RESI’s focus on connecting early-stage life science and healthcare companies with investors, strategic partners, and industry leaders who can accelerate breakthrough therapies.

Bayer Co.Lab’s will be sponsoring a 2-hour session at RESI Boston 2026:

Connecting Asian Biotech Innovation with Global Partners: A Bayer Co.Lab Showcase

Tuesday, September 22, 2:00 – 4:00pm EST

The showcase will bring seven emerging biotechnology companies from Korea and Japan to the RESI stage, highlighting innovative approaches across various therapeutic modalities.

RSVP for Bayer Co.Lab Showcase

artiCure | Korea

Tumor-selective replicating gene therapy targeting solid tumors

Crafton Biotechnology | Japan

mRNA therapeutics supported by advanced computational approaches

Curigin | Korea

RNA-based therapeutic technologies across multiple disease areas

Elisigen | Korea

Next-generation gene therapy with programs in ophthalmology

Genome & Company | Korea

Microbiome-driven therapeutic discovery and development

ILIAS Biologics | Korea

Exosome-based therapeutics for inflammatory and fibrotic diseases

Kanjin Therapeutics | Japan

RNA therapeutics, including siRNA and antisense approaches, for areas of unmet medical need

The program reflects a growing opportunity to connect promising innovation emerging from Asian biotech ecosystems with global pharmaceutical partners, investors, and other strategic collaborators. By bringing Korean and Japanese companies directly into the RESI community, the showcase will create a forum for companies to present their science, build international relationships, and explore pathways for global development and partnership.

Meet Bayer at RESI Boston

Bayer will have a strong presence at RESI Boston, with senior representatives spanning Co.Lab and BD & Licensing departments.

Alberto Nobili Sr. Director, Strategy and Portfolio at Co.Lab	Nobuhiro Kazama Head of Collaborate to Cure Japan Hub	Ilona Gutcher Senior Director, BD&L Oncology
Carla Klattenhoff Senior Director / Scientific US Lead for Research and Early Development in CV, Renal and Immunology	Shivaranjani Sridharan Executive Director, Business Development & Licensing

Their participation gives RESI attendees an opportunity to engage with Bayer leaders representing multiple areas of scientific and strategic interest and to gain greater insight into how a global pharmaceutical company approaches external innovation and collaboration.

Bringing Global Innovators Together in Boston

RESI has always been built around a simple idea: great science can come from anywhere, but moving it forward requires the right connections.

Bayer Co.Lab’s participation as Title Sponsor of RESI Boston 2026 reinforces that mission. From supporting emerging entrepreneurs to creating new connections between Asian biotech innovators and the global life science ecosystem, the collaboration will bring another important dimension to this year’s RESI Boston.

Join Bayer Co.Lab and the global early-stage life science community at RESI Boston 2026!

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Japan has world-class science, deep pharmaceutical expertise, and a rich pipeline of emerging life science technology. It is now delivering an innovation bridge that connects that innovation to the global life science community.

At RESI Boston 2026, our 8th annual Global Family Office BioForum Luncheon will bring together international family offices for a private, invitation-only conversation about the emerging bridge between Japan and the rest of the world. I will be joined by Keiko Kobayashi of the Kobe Biomedical Innovation Cluster (KBIC) and Rick Berenson, Managing Director of Venzyme Catalyst.

KBIC is one of Japan’s largest life science clusters, and our work together is centered on three objectives: helping Japanese technology assets enter the global arena, bringing international investors and strategic partners closer to Japan’s innovation ecosystem, and fostering cross-border investment syndicates that connect Japanese and international investors around opportunities in both markets.

The pieces are coming together. KBIC brings the Japanese ecosystem, company pipeline, and government relationships. Venzyme Catalyst brings early-stage assessment, shaping, and de-risking. LSN brings commercialization preparation, RESI, BD Assist, and its global network of investors and licensing partners. Keiko will share what KBIC is building in Japan, while Rick and I will explain how the commercialization engine connects regional innovation to the global marketplace.

Then we will do what has made the BioForum work for eight years: get out of the way and let the room work. The real value is the conversation among family offices as they compare perspectives, share experiences, and build relationships with peers. Attendance is limited and by invitation only. Family offices interested in attending can reply to this newsletter or contact Life Science Nation to request an invitation.

Global Family Office BioForum Luncheon
Tuesday, September 22, 2026, 12:00 to 1:00 pm
Westin Copley Place, Boston
Private and invitation only

RSVP for GFOB Here

Featuring: